Header Logo

Connection

GUILLERMO GARCIA-MANERO to Antimetabolites, Antineoplastic

Back to Details
This is a "connection" page, showing publications GUILLERMO GARCIA-MANERO has written about Antimetabolites, Antineoplastic.
GUILLERMO GARCIA-MANERO
Connection Strength
7.429
Antimetabolites, Antineoplastic
  1. A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):658-663.e2.
    View in: PubMed
    Score: 0.411
  2. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017 Jul; 92(7):599-606.
    View in: PubMed
    Score: 0.382
  3. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr; 30(4):889-96.
    View in: PubMed
    Score: 0.341
  4. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Am J Hematol. 2015 Sep; 90(9):831-41.
    View in: PubMed
    Score: 0.339
  5. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Leuk Res. 2015 May; 39(5):520-4.
    View in: PubMed
    Score: 0.328
  6. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015 Jan; 2(1):e12-20.
    View in: PubMed
    Score: 0.323
  7. Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 Nov; 167(3):356-65.
    View in: PubMed
    Score: 0.314
  8. Reply to T. Radivoyevitch et al. J Clin Oncol. 2014 Jan 01; 32(1):61.
    View in: PubMed
    Score: 0.299
  9. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):592-6.
    View in: PubMed
    Score: 0.291
  10. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013 Jul 10; 31(20):2548-53.
    View in: PubMed
    Score: 0.290
  11. Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy. Best Pract Res Clin Haematol. 2012 Dec; 25(4):427-35.
    View in: PubMed
    Score: 0.278
  12. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol. 2011 Feb 10; 29(5):516-23.
    View in: PubMed
    Score: 0.246
  13. Safety and efficacy of azacitidine in myelodysplastic syndromes. Drug Des Devel Ther. 2010 Sep 24; 4:221-9.
    View in: PubMed
    Score: 0.241
  14. Evaluating new treatment options for MDS. Clin Adv Hematol Oncol. 2007 Nov; 5(11):1-9; quiz 10-2.
    View in: PubMed
    Score: 0.197
  15. Use of hypomethylating agents in myelodysplastic syndromes. Clin Adv Hematol Oncol. 2007 Jul; 5(7):544-52.
    View in: PubMed
    Score: 0.192
  16. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. Clin Lymphoma Myeloma Leuk. 2022 04; 22(4):236-250.
    View in: PubMed
    Score: 0.129
  17. A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. Leuk Res. 2021 05; 104:106555.
    View in: PubMed
    Score: 0.124
  18. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma. 2019 09; 60(9):2207-2213.
    View in: PubMed
    Score: 0.108
  19. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019 Jan; 6(1):e29-e37.
    View in: PubMed
    Score: 0.106
  20. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 2018 05; 32(5):1094-1105.
    View in: PubMed
    Score: 0.101
  21. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 09 28; 130(13):1514-1522.
    View in: PubMed
    Score: 0.097
  22. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC). Leuk Lymphoma. 2017 06; 58(6):1325-1331.
    View in: PubMed
    Score: 0.092
  23. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016 Mar 22; 7(12):14172-87.
    View in: PubMed
    Score: 0.088
  24. Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncol. 2016 Feb; 12(3):293-302.
    View in: PubMed
    Score: 0.087
  25. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leuk Res. 2016 Feb; 41:43-7.
    View in: PubMed
    Score: 0.087
  26. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. PLoS One. 2015; 10(8):e0135520.
    View in: PubMed
    Score: 0.085
  27. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015 Mar 15; 121(6):876-82.
    View in: PubMed
    Score: 0.080
  28. Novel drugs for older patients with acute myeloid leukemia. Leukemia. 2015 Apr; 29(4):760-9.
    View in: PubMed
    Score: 0.079
  29. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014 Jun; 28(6):1280-8.
    View in: PubMed
    Score: 0.075
  30. Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S289-94.
    View in: PubMed
    Score: 0.074
  31. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol. 2013 Mar; 88(3):198-200.
    View in: PubMed
    Score: 0.071
  32. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):131-8.
    View in: PubMed
    Score: 0.070
  33. Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):292-5.
    View in: PubMed
    Score: 0.070
  34. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012 Nov; 26(11):2428-31.
    View in: PubMed
    Score: 0.068
  35. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011 Jun 20; 29(18):2521-7.
    View in: PubMed
    Score: 0.063
  36. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010 Aug 15; 116(16):3830-4.
    View in: PubMed
    Score: 0.060
  37. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010 Nov 25; 116(22):4422-9.
    View in: PubMed
    Score: 0.060
  38. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010 Oct 28; 116(17):3163-70.
    View in: PubMed
    Score: 0.059
  39. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol. 2010 Aug; 7(8):433-44.
    View in: PubMed
    Score: 0.059
  40. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk. 2010 Jun; 10(3):205-10.
    View in: PubMed
    Score: 0.059
  41. Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther. 2010 Jan; 10(1):9-22.
    View in: PubMed
    Score: 0.057
  42. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009 Dec 15; 115(24):5746-51.
    View in: PubMed
    Score: 0.057
  43. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009 Aug 10; 27(23):3842-8.
    View in: PubMed
    Score: 0.055
  44. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009 May 01; 115(9):1899-905.
    View in: PubMed
    Score: 0.055
  45. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. Clin Adv Hematol Oncol. 2008 Dec; 6(12):1-15.
    View in: PubMed
    Score: 0.053
  46. A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008 Sep; 22(9):1680-4.
    View in: PubMed
    Score: 0.051
  47. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008 Jun; 112(11):2341-51.
    View in: PubMed
    Score: 0.051
  48. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res. 2007 Jul 15; 13(14):4225-32.
    View in: PubMed
    Score: 0.048
  49. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 01; 109(1):52-7.
    View in: PubMed
    Score: 0.045
  50. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res. 2006 May 15; 66(10):5495-503.
    View in: PubMed
    Score: 0.044
  51. Decitabine in myelodysplastic syndromes: viewpoints. Drugs. 2006; 66(7):959-60.
    View in: PubMed
    Score: 0.043
  52. DNA methylation in haematological malignancies: the role of decitabine. Expert Opin Investig Drugs. 2003 Dec; 12(12):1985-93.
    View in: PubMed
    Score: 0.038
  53. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024 Feb; 99(2):E32-E36.
    View in: PubMed
    Score: 0.037
  54. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004 Mar 01; 103(5):1635-40.
    View in: PubMed
    Score: 0.037
  55. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003 Aug 01; 98(3):522-8.
    View in: PubMed
    Score: 0.037
  56. Azacitidine Monotherapy in Patients With Treatment-Na?ve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2023 02; 23(2):127-137.
    View in: PubMed
    Score: 0.035
  57. What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)? Leuk Lymphoma. 2021 11; 62(11):2762-2767.
    View in: PubMed
    Score: 0.032
  58. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018 03; 93(3):401-407.
    View in: PubMed
    Score: 0.025
  59. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leuk Lymphoma. 2015 Feb; 56(2):390-4.
    View in: PubMed
    Score: 0.020
  60. Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):93-7.
    View in: PubMed
    Score: 0.019
  61. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6.
    View in: PubMed
    Score: 0.018
  62. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin Drug Metab Toxicol. 2011 May; 7(5):661-72.
    View in: PubMed
    Score: 0.016
  63. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007 Jan 15; 109(2):265-73.
    View in: PubMed
    Score: 0.012
  64. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005 Aug 01; 104(3):547-54.
    View in: PubMed
    Score: 0.011
  65. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005 Jun 10; 23(17):3948-56.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.